Attacking tumor cells with a dual ligand for innate immune receptors

Johan Garaude,J Magarian Blander

doi:10.18632/oncotarget.484

Johan Garaude, J Magarian Blander

Open Access

https://doi.org/10.18632/oncotarget.484

Copy DOI

Abstract

Attacking tumor cells with a dual ligand for innate immune receptors

Highlights

Nod-like receptors (NLRs) are being implicated in an increasing number of biological processes including carcinogenesis
Among NLR ligands, the bacterial protein flagellin is of particular interest since it is recognized by Toll-like receptor 5 (TLR5) and the NLR NAIP5, which partners with the NLR NLRC4 (NLR family, CARD domain containing protein 4) in the cytosol [4,5]
We tested this possibility by introducing flagellin into different tumor cell lines, a strategy that abrogated tumor development upon subcutaneous or intravenous injection of these flagellin-expressing cells, and induced DCmediated tumor antigen presentation to CD4+ and CD8+ T cells [6]

Summary

Introduction

Nod-like receptors (NLRs) are being implicated in an increasing number of biological processes including carcinogenesis. Among PRRs, the NLRs constitute a recently identified family of cytosolic innate immune receptors that have been implicated in various diseases including cancer [1]. This signal can efficiently be provided by engagement of another family of innate immune receptors, the Toll-like receptors (TLRs), activation of which leads to cytokine production, T cell co-stimulatory molecule expression, and enhanced antigen presentation [1,2].

Results

Conclusion